SAVA · Cassava Sciences, Inc.

Alzheimer's developer whose simufilam failed Phase 3 amid data-integrity probes

Risiko 9/10 · HIGH · trial failure · $—

Kennzahlen

• Price —
• Market cap —
• P/E (ttm) —
• Div yield —
• 52-wk range —

Wichtigste Risiken

• Lead drug (simufilam) Phase 3 failure (Shareholders) — EXTREME
• Data-integrity allegations & SEC/DOJ scrutiny (Credibility & legal) — EXTREME
• Pipeline thin / pivot risk post-failure (Shareholders) — EXTREME
• Litigation & settlement overhang (Existing holders) — HIGH

Fazit

With its lead program failed and credibility damaged, Cassava is a deeply speculative shell-of-a-story stock dependent on an uncertain pivot.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.